157 related articles for article (PubMed ID: 37684679)
1. PRevalence of the Eosinophilic Phenotype Among SeveRE asthma patients in Lebanon: results of the PREPARE study.
Abi Saleh W; Alameh Z; Aoun Bacha Z; Bahous J; Bou Khalil P; Chahine Z; Chami H; Dabar G; Dheiny H; Dib A; Farhat D; Irani C; Juvelekian G; Kanj N; Mansour B; Riachi M; Waked M; Yassine M; Youakim C; Zeinedine S; Zaitoun F
Allergy Asthma Clin Immunol; 2023 Sep; 19(1):80. PubMed ID: 37684679
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of eosinophilic, atopic, and overlap phenotypes among patients with severe asthma in Saudi Arabia: a cross-sectional study.
Al-Jahdali H; Wali S; Albanna AS; Allehebi R; Al-Matar H; Fattouh M; Beekman M
BMC Pulm Med; 2022 Feb; 22(1):67. PubMed ID: 35177038
[TBL] [Abstract][Full Text] [Related]
3. A Multi-Center Study of the Prevalence and Characteristics of Eosinophilic Phenotype and High IgE Levels Among Chinese Patients with Severe Asthma.
Ko FW; Wang JKL; Hui DSC; Chan JWM; Cheung PS; Yeung YC; Sin KM; Ip MS
J Asthma Allergy; 2023; 16():173-182. PubMed ID: 36721738
[TBL] [Abstract][Full Text] [Related]
4. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.
McDowell PJ; Diver S; Yang F; Borg C; Busby J; Brown V; Shrimanker R; Cox C; Brightling CE; Chaudhuri R; Pavord ID; Heaney LG;
Lancet Respir Med; 2021 Oct; 9(10):1174-1184. PubMed ID: 33971168
[TBL] [Abstract][Full Text] [Related]
5. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
[TBL] [Abstract][Full Text] [Related]
6. Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort.
Heaney LG; Perez de Llano L; Al-Ahmad M; Backer V; Busby J; Canonica GW; Christoff GC; Cosio BG; FitzGerald JM; Heffler E; Iwanaga T; Jackson DJ; Menzies-Gow AN; Papadopoulos NG; Papaioannou AI; Pfeffer PE; Popov TA; Porsbjerg CM; Rhee CK; Sadatsafavi M; Tohda Y; Wang E; Wechsler ME; Alacqua M; Altraja A; Bjermer L; Björnsdóttir US; Bourdin A; Brusselle GG; Buhl R; Costello RW; Hew M; Koh MS; Lehmann S; Lehtimäki L; Peters M; Taillé C; Taube C; Tran TN; Zangrilli J; Bulathsinhala L; Carter VA; Chaudhry I; Eleangovan N; Hosseini N; Kerkhof M; Murray RB; Price CA; Price DB
Chest; 2021 Sep; 160(3):814-830. PubMed ID: 33887242
[TBL] [Abstract][Full Text] [Related]
7. Refractory asthma phenotyping based on immunoglobulin E levels and eosinophilic counts: A real life study.
Lababidi HM; AlSowayigh OM; BinHowemel SF; AlReshaid KM; Alotaiq SA; Bahnassay AA
Respir Med; 2019; 158():55-58. PubMed ID: 31605922
[TBL] [Abstract][Full Text] [Related]
8. Toward a better understanding of severe asthma phenotypes in Latin America: results from the PREPARE study.
Maspero J; Pavie J; Torres-Duque CA; Montero-Arias F; Cerino-Javier R; Rovira F; Beekman MJHI
Curr Med Res Opin; 2023 Apr; 39(4):627-638. PubMed ID: 36740960
[TBL] [Abstract][Full Text] [Related]
9. Asthmatics with concordant eosinophilic disease classified according to their serum IgE status.
Gerday S; Schleich F; Henket M; Guissard F; Paulus V; Louis R
Respir Med Res; 2021 May; 79():100797. PubMed ID: 33383519
[TBL] [Abstract][Full Text] [Related]
10. Severe asthma treatment patterns: A multicenter observational study in the Gulf region.
Al-Ahmad M; Mobayed H; Al Busaidi N; Iqbal MN; Al Mubaihsi S; Khadadah M; Kassem A; Abuzakouk M; Uzbeck M; Al Zaabi A; Farouk H
World Allergy Organ J; 2022 May; 15(5):100647. PubMed ID: 35663273
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of Severe Non-Eosinophilic Asthma: Analysis of Data from 1075 Patients Included in the FASE-CPHG Study.
Portel L; Fabry-Vendrand C; Texier N; Schwartz D; Capdepon A; Thabut G; Debieuvre D
J Asthma Allergy; 2023; 16():9-21. PubMed ID: 36628339
[TBL] [Abstract][Full Text] [Related]
12. A retrospective observational study on pheno-endotypes of severe asthma among adults attending asthma clinic in a tertiary care centre in India.
Talwar D; Talwar D; Jain N; Prajapat D; Pahuja S
Lung India; 2022; 39(5):393-400. PubMed ID: 36629198
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of the eosinophilic phenotype among severe asthma patients in Brazil: the BRAEOS study.
Athanazio R; Stelmach R; Antila M; Souza-Machado A; Arruda LK; Cerci Neto A; Serpa FS; Blanco DC; Lima M; Bianchi Júnior P; Penha M; Rabahi MF
J Bras Pneumol; 2022; 48(3):e20210367. PubMed ID: 35830052
[TBL] [Abstract][Full Text] [Related]
14. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
[TBL] [Abstract][Full Text] [Related]
15. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
Wenzel S; Castro M; Corren J; Maspero J; Wang L; Zhang B; Pirozzi G; Sutherland ER; Evans RR; Joish VN; Eckert L; Graham NM; Stahl N; Yancopoulos GD; Louis-Tisserand M; Teper A
Lancet; 2016 Jul; 388(10039):31-44. PubMed ID: 27130691
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression.
Pelaia C; Crimi C; Benfante A; Caiaffa MF; Calabrese C; Carpagnano GE; Ciotta D; D'Amato M; Macchia L; Nolasco S; Pelaia G; Pellegrino S; Scichilone N; Scioscia G; Spadaro G; Valenti G; Vatrella A; Crimi N
J Asthma Allergy; 2021; 14():163-173. PubMed ID: 33654413
[TBL] [Abstract][Full Text] [Related]
17. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials.
Bernstein JA; Virchow JC; Murphy K; Maspero JF; Jacobs J; Adir Y; Humbert M; Castro M; Marsteller DA; McElhattan J; Hickey L; Garin M; Vanlandingham R; Brusselle G
Lancet Respir Med; 2020 May; 8(5):461-474. PubMed ID: 32066536
[TBL] [Abstract][Full Text] [Related]
18. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years.
Knorr B; Franchi LM; Bisgaard H; Vermeulen JH; LeSouef P; Santanello N; Michele TM; Reiss TF; Nguyen HH; Bratton DL
Pediatrics; 2001 Sep; 108(3):E48. PubMed ID: 11533366
[TBL] [Abstract][Full Text] [Related]
19. Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma.
Tran TN; Zeiger RS; Peters SP; Colice G; Newbold P; Goldman M; Chipps BE
Ann Allergy Asthma Immunol; 2016 Jan; 116(1):37-42. PubMed ID: 26707771
[TBL] [Abstract][Full Text] [Related]
20. [Distribution of airway inflammation phenotype in patients with bronchial asthma and its correlation with control level].
Li HW; Lin JT; Nong Y; Ren ZC; Han QQ
Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(22):1692-1697. PubMed ID: 31216813
[No Abstract] [Full Text] [Related]
[Next] [New Search]
